Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration


Gotham Therapeutics has selected ZoBio to initiate a collaboration on the development of small molecules targeting epitranscriptomic targets. This collaboration has now resulted in several lead candidates for the METTL3/METTL14 complex.

With 15 years of experience, ZoBio is the proven partner for biophysics driven, fragment based drug discovery. We are dedicated to achieving the best science and highest level of transparency.

Our integrated discovery engine progresses projects from gene-to-lead. High throughput protein engineering and production, diverse, novel fragment libraries, proprietary biophysical screening technologies and complementary structural biology approaches have been tailored to provide validated data at every step of the process. The right combination of these various disciplines generates actionable medicinal chemistry hypotheses for small molecule modulators of a great variety of pharmacological targets, including those that have previously been out of reach.

‘In a sector that is still in its infancy, we have made tangible progress with our partner ZoBio to develop small molecule leads against a portfolio of epitranscriptomic targets just 14 months after initiation of the project,’ commented Dr. Lee Babiss, Chief Executive Officer of Gotham Therapeutics. ‘Today’s news is also a validation of the semi-virtual model we use and the productivity of our network with best-in-class CROs.’

‘With METTL3/METTL14 being among the more obvious approaches in epitranscriptomics, the quality of the hit matter pursued is going to be a key differentiating factor,’ added Dr, Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. ‘Together with ZoBio, we have not just successfully identified the initial candidates for Gotham’s first pipeline program but also established a robust process from gene to lead as a platform for additional projects to come.’